Drug Trial Radar · NCT02105948
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
Last checked: Nov 20, 2026Latest source record: Aug 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
837
Actual
Start
Apr 15, 2014
Primary completion
Jan 17, 2017
Study completion Jan 17, 2017
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection. In severe COPD patients, sputum eosinophils levels are elevated similar as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD patients would translate into a reduction of COPD exacerbations. The study will determine the reduction in exacerbations in subjects who are above and below the baseline blood eosinophil count of at least 150 cells/microlitres. The study will evaluate the efficacy and safety of mepolizumab on the frequency of moderate and severe exacerbations in COPD subjects at high risk of exacerbations, despite the use of optimized standard of care background therapy. Overall in this study, a total of 800 subjects will be randomised in 1:1 ratio to receive placebo or mepolizumab (100 milligram (mg)) administered SC. The total duration of this study will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
MepolizumabDrug
Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
PlaceboDrug
Sterile 0.9% sodium chloride solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Moderate or Severe Exacerbations in Participants in the High StratumTime frame: From randomization to Week 52
- Rate of Moderate or Severe Exacerbations in the mITT PopulationTime frame: From randomization to Week 52
Locations
116 sites in 16 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Rochester, Minnesota
GSK Investigational Site
Saint Charles, Missouri
GSK Investigational Site
New York, New York
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Gastonia, North Carolina
GSK Investigational Site
Huntersville, North Carolina
GSK Investigational Site
Wilmington, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Medford, Oregon
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Easley, South Carolina
GSK Investigational Site
Fort Mill, South Carolina
GSK Investigational Site
Gaffney, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Seneca, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Abingdon, Virginia
GSK Investigational Site
Liverpool, Australia
GSK Investigational Site
Cairns, Queensland, Australia
GSK Investigational Site
Daw Park, South Australia, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Frankston, Victoria, Australia
GSK Investigational Site
Murdoch, Western Australia, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Erpent, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Ostend, Belgium
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Sherwood Park, Alberta, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Gatineau, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.